Valuation: China Resources Double-Crane Pharmaceutical Co.,Ltd.

Market Cap 17.49B 2.58B 2.25B 2.08B 1.92B 3.61B 248B 3.69B 24.86B 9.78B 122B 9.69B 9.48B 419B P/E 2026 *
9.99x
P/E 2027 * 9.38x
Enterprise Value 17.49B 2.58B 2.25B 2.08B 1.92B 3.61B 248B 3.69B 24.86B 9.78B 122B 9.69B 9.48B 419B EV / Sales 2026 *
1.51x
EV / Sales 2027 * 1.44x
Free-Float
37.82%
Yield 2026 *
3.01%
Yield 2027 * 3.13%
07-15 China Resources Pharma Unit Emerges Top Bidder for Lier Chemical Stake MT
07-14 China Resources Double-Crane Pharmaceutical Co.,Ltd. proposed to acquire 23.5% stake in Lier Chemical Co.,LTD. from Sichuan Chemical Technology Co., Ltd. and Sichuan Jiuyuan Investment Holding Group Ltd. CI
07-06 China Approves Double-Crane Pharmaceutical's Progesterone Capsules MT
07-02 CR Double-Crane Pharma's Unit Gets EU's Certificate of Suitability for Sodium Valproate MT
07-02 CR Double-Crane Pharmaceutical Gains China Approval for Children's Constipation Drug MT
06-23 China Resources Double-Crane Pharmaceutical Co.,Ltd. completed the acquisition of Nanjing Xinbai Pharmaceutical Co., Ltd. from Jiangxi Boya Pharmaceutical Investment Co., Ltd and China Resources Boya Bio-pharmaceutical Group Co.,Ltd. CI
06-16 CR Double-Crane Units Secure China Approval for Three Drugs MT
05-11 CR Double-Crane Pharma Unit Obtains China Nod for Ezetimibe MT
05-10 CR Double-Crane Pharmaceutical's Unit Gets Registration Certificate for Electrolyte Product MT
04-26 CR Double-Crane's Profit, Revenue Fall in Q1 MT
04-24 China Resources Double-Crane Pharmaceutical Co.,Ltd. entered into letter of intent to acquire Nanjing Xinbai Pharmaceutical Co., Ltd. from Jiangxi Boya Pharmaceutical Investment Co., Ltd and China Resources Boya Bio-pharmaceutical Group Co.,Ltd for approximately CNY 240 million. CI
04-24 China Resources Double-Crane Pharmaceutical Q1 net profit down 4.3% Y/Y RE
04-24 China Resources Pharmaceutical says Q1 net profit for CR Double-Crane is RMB501.4 mln RE
1 day-3.26%
1 week+2.17%
Current month+5.55%
1 month+3.36%
3 months-7.49%
6 months-8.68%
Current year-7.44%
1 week 16.49
Extreme 16.49
17.65
1 month 15.29
Extreme 15.29
17.65
Current year 15.29
Extreme 15.29
19.08
1 year 15.29
Extreme 15.29
22.14
3 years 14.8
Extreme 14.8
26.15
5 years 10.95
Extreme 10.95
37.44
10 years 10.66
Extreme 10.66
37.44
Manager TitleAgeSince
President - 2024-10-24
President - 2023-09-20
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 67 2021-07-11
Director/Board Member 68 2010-05-31
Director/Board Member 66 2018-06-21
Date Insider Type Main position Quantity % Market Cap.
12/21/22 Buy

Chairman

5,000 0.0005%
12/21/22 Buy

Director

10,000 0.0010%
12/20/22 Buy

Director

5,000 0.0005%
Change 5-day change 1-year change 3-year change Capi.($)
-3.26%+2.17%-12.78%+1.26% 2.58B
+0.85%-0.80%+52.79%+161.33% 1,051B
+1.23%-1.53%+54.58%+59.08% 609B
+0.04%+2.58%+34.47%+86.33% 450B
+0.78%-0.71%+29.28%+24.10% 330B
+1.41%+0.58%+35.44%+40.67% 284B
-0.27%-1.87%+22.34%+22.51% 263B
-1.76%+2.37%-20.43%-38.00% 223B
-1.42%+0.80%+24.27%+57.50% 198B
-1.48%+3.43%+24.08%+71.67% 167B
Average -0.39%+0.62%+24.40%+48.64% 357.76B
Weighted average by Cap. +0.37%+0.02%+37.47%+79.57%

Financials

2026 *2027 *
Net sales 11.59B 1.71B 1.49B 1.38B 1.27B 2.4B 165B 2.45B 16.48B 6.48B 80.66B 6.42B 6.28B 278B 12.18B 1.8B 1.57B 1.45B 1.34B 2.52B 173B 2.57B 17.32B 6.81B 84.75B 6.75B 6.6B 292B
Net income 1.76B 259M 227M 209M 193M 363M 24.96B 371M 2.5B 983M 12.23B 973M 952M 42.09B 1.87B 276M 241M 223M 205M 387M 26.61B 396M 2.66B 1.05B 13.03B 1.04B 1.01B 44.87B
Net Debt - -
Logo China Resources Double-Crane Pharmaceutical Co.,Ltd.
China Resources Double-Crane Pharmaceutical Co Ltd is a China-based company primarily engaged in the new drug research and development, preparation production, drug sales, and active pharmaceutical ingredients (API) production. The Company operates two segments. The Infusion segment is mainly engaged in the production and sale of infusion products and the provision of services. The Non-Infusion segment is mainly engaged in the production and sale of non-infusion products and the provision of services. The Company's chronic disease business products include compound reserpine triamterene tablets, gliquidone tablets and others. The Company's specialty business products include teniposide injection, busulfan injection and others. The Company's infusion business products include basic infusion, therapeutic infusion, nutritional infusion and other multi-category infusion products. The Company's API business products include valsartan, amlodipine, pregabalin and others.
Employees
13,184
Date Price Change Volume
26-07-17 CN¥16.93 -3.26% 13,963,846
26-07-16 CN¥17.50 +1.45% 16,915,936
26-07-15 CN¥17.25 +2.31% 15,295,615
26-07-14 CN¥16.86 +0.96% 9,293,813
26-07-13 CN¥16.70 +0.78% 8,760,650
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
16.93CNY
Average target price
25.32CNY
Spread / Average Target
+49.59%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 600062 Stock